HER-2 Expression in Immunohistochemistry Has No Prognostic Significance in Gastric Cancer Patients

HER-2 Expression in Immunohistochemistry Has No Prognostic Significance in Gastric Cancer Patients

The role of HER-2 expression as a prognostic factor in gastric cancer (GC) is still controversial. The aim of the study was to asses HER-2 status, its correlations with clinicopathological parameters, and prognostic impact in GC patients. Tumor samples were collected from 78 patients who had undergo...

Full description

Bibliographic Details
Main Authors: Halon, Agnieszka, Donizy, Piotr, Biecek, Przemyslaw, Rudno-Rudzinska, Julia, Kielan, Wojciech, Matkowski, Rafal
Format: Online
Language:English
Published: The Scientific World Journal 2012
Online Access:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3356756/
id pubmed-3356756
recordtype oai_dc
spelling pubmed-33567562012-05-29 HER-2 Expression in Immunohistochemistry Has No Prognostic Significance in Gastric Cancer Patients Halon, Agnieszka Donizy, Piotr Biecek, Przemyslaw Rudno-Rudzinska, Julia Kielan, Wojciech Matkowski, Rafal Research Article The role of HER-2 expression as a prognostic factor in gastric cancer (GC) is still controversial. The aim of the study was to asses HER-2 status, its correlations with clinicopathological parameters, and prognostic impact in GC patients. Tumor samples were collected from 78 patients who had undergone curative surgery. In order to evaluate the intensity of immunohistochemical (IHC) reactions two scales were applied: the immunoreactive score according to Remmele modified by the authors and standardised Hercep test score modified for GC by Hofmann et al. The HER-2 overexpression was detected by IHC in 23 (29.5%) tumors in Hercep test (score 2+/3+) and in 24 (30.7%) in IRS scale (IRS 4–12). The overexpression of HER-2 was associated with poorly differentiated tumors, but this correlation was not significant (P = 0.064). No relationship was found between HER-2 expression and primary tumor size and degree of spread to regional lymph nodes. Both univariate and multivariate analyses revealed that TNM stage and patient's age were the crucial negative prognostic factors. No correlation was observed between patient survival and expression of HER-2 estimated using both scales. This research did not confirm HER-2 expression (evaluated with immunohistochemistry) value as a prognostic tool in GC. The Scientific World Journal 2012-05-03 /pmc/articles/PMC3356756/ /pubmed/22645475 http://dx.doi.org/10.1100/2012/941259 Text en Copyright © 2012 Agnieszka Halon et al. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
repository_type Open Access Journal
institution_category Foreign Institution
institution US National Center for Biotechnology Information
building NCBI PubMed
collection Online Access
language English
format Online
author Halon, Agnieszka
Donizy, Piotr
Biecek, Przemyslaw
Rudno-Rudzinska, Julia
Kielan, Wojciech
Matkowski, Rafal
spellingShingle Halon, Agnieszka
Donizy, Piotr
Biecek, Przemyslaw
Rudno-Rudzinska, Julia
Kielan, Wojciech
Matkowski, Rafal
HER-2 Expression in Immunohistochemistry Has No Prognostic Significance in Gastric Cancer Patients
author_facet Halon, Agnieszka
Donizy, Piotr
Biecek, Przemyslaw
Rudno-Rudzinska, Julia
Kielan, Wojciech
Matkowski, Rafal
author_sort Halon, Agnieszka
title HER-2 Expression in Immunohistochemistry Has No Prognostic Significance in Gastric Cancer Patients
title_short HER-2 Expression in Immunohistochemistry Has No Prognostic Significance in Gastric Cancer Patients
title_full HER-2 Expression in Immunohistochemistry Has No Prognostic Significance in Gastric Cancer Patients
title_fullStr HER-2 Expression in Immunohistochemistry Has No Prognostic Significance in Gastric Cancer Patients
title_full_unstemmed HER-2 Expression in Immunohistochemistry Has No Prognostic Significance in Gastric Cancer Patients
title_sort her-2 expression in immunohistochemistry has no prognostic significance in gastric cancer patients
description The role of HER-2 expression as a prognostic factor in gastric cancer (GC) is still controversial. The aim of the study was to asses HER-2 status, its correlations with clinicopathological parameters, and prognostic impact in GC patients. Tumor samples were collected from 78 patients who had undergone curative surgery. In order to evaluate the intensity of immunohistochemical (IHC) reactions two scales were applied: the immunoreactive score according to Remmele modified by the authors and standardised Hercep test score modified for GC by Hofmann et al. The HER-2 overexpression was detected by IHC in 23 (29.5%) tumors in Hercep test (score 2+/3+) and in 24 (30.7%) in IRS scale (IRS 4–12). The overexpression of HER-2 was associated with poorly differentiated tumors, but this correlation was not significant (P = 0.064). No relationship was found between HER-2 expression and primary tumor size and degree of spread to regional lymph nodes. Both univariate and multivariate analyses revealed that TNM stage and patient's age were the crucial negative prognostic factors. No correlation was observed between patient survival and expression of HER-2 estimated using both scales. This research did not confirm HER-2 expression (evaluated with immunohistochemistry) value as a prognostic tool in GC.
publisher The Scientific World Journal
publishDate 2012
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3356756/
_version_ 1611531441478303744

Similar Items